Innovations Clinical Hospital «NEUROVITA»
For thirty years we have been accumulating and processing the data of fundamental research and evidence about genomics, transcriptomics and proteomic of a hematopoietic stem cell (HSC)and neural stem cell (NSC) of a human. Our working team was lucky to be guided by the top experts: Prof. Mikhail I. Davydov, the oncologist, the member of the Russian Academy of Science (RAS); Prof. Gennadiy T. Sukhikh, the expert in immunology, the member of the RAS; Prof. Vadim P. Chekhonin, the expert in cell therapy, the member of the RAS; Prof. Yaryghin, the expert in neurobiology, the member of the RAS, and Prof. Shumakov, the expert in transplantology, the member of the RAS. These data are published in 15 scientific monographs, 220 publications in the peer reviewed national and international journals and protected by over 35 patents of inventions and applications.
The result is the promising hypothesis that fatal oncological, neurodegenerative and autoimmune diseases of the human civilization as well as aging are not the disorders of the pathospecific (cancer-specific, neurospecific and so on) protein molecules in the differentiated cells of the specialized tissue, but the post-genomic diseases of the hematopoietic stem cells (HSCs), tissue-specific progenitors and stem cells (SCs). This hypothesis provided the foundation for our novel biotechnologies.
The hospital attracted private investment to establish the material basis and initiated a highly technological business in the area of personalized post-genomic and regenerative medicine. We have developed the following innovative biomedical technologies:
- artificial neural tissue;
- the therapy of organic injuries of the brain and spinal cord with the HSCs;
- ultra-early molecular-biological diagnostic of cancer and neurodegenerative diseases by mapping and profiling membrane antigens of the HSCs and HPCs;
- precision immunotherapy of cancer;
- anti-tumor molecularly-targeted cell products;
- remote multi-wave radioneuroengineering of the brain and spinal cord;
- anti-tumor artificial cell-pharmaceutical immunity.
A personalized approach is the basis for our novel biomedical platform to treat injuries of the organs and tissues, and especially the neural tissue of the brain and spinal cord. The platform is best illustrated by the patented medical biotechnology Remote-control contactless multi-wave radioneuroengineering of the brain and spinal cord of the human (see details).
The Hospital has developed a novel biomedical platform of the therapy of hereditary diseases of the nervous system (HDNS). We admit the impossibility to currently cure the HDNS as every cell of the patient with HDNS contains the defect but we lay our hopes on the nature-like novel technology of the binary DNA-targeted biotherapy to stabilize the genome. All components of it are approved for clinical use and are able to arrest the progress of the HDNC to prevent relapses and lethal oncological, autoimmune and neurodegenerative complications (see details).
The Hospital has developed a biomedical platform to extend the lifespan of humans and to achieve active longevity. For it, the autologous HSCs are gathered at a young age and the proteomic mapping and profiling of the membrane antigens of HSCs helps detect the main diseases of civilization in them at an early stage before clinical manifestation of the disease. The harvested mononuclear cells of peripheral blood, HSCs and HPCs can be cryopreserved and stored. They avoid the systemic process of aging and thus can be used in elderly age. The technology extends the lifespan in mammals by 28-30%, which is experimentally proven. We are starting the project to gather the HSCs and to further store them in a cryobank (see details).
We also lay hopes on a novel cell product Hemacell that is based on the thawed HSCs in the leukapheresis product of mononuclear cells of peripheral blood that has been incubated with Panagen therapeutic substance. The combination of the cellular-pharmaceutical cell product Hemacell demonstrated the pronounced anti-tumor effect, neuroregenerative potential in the recovery of the brain and spinal cord and rejuvenating effect in a human organism. The technology is protected by the patent for the invention of Russia. The product can be used in the patients with Alzheimer’s disease and other types of dementia. The preclinical trials are completed, the protocols of the clinical trials are ready. The clinical trials of the cell product start after the approval of the Ministry of Healthcare of Russia. In 2021 young scientists of our team headed by Sergey S.Bogachov (Novosibirsk) were awarded with the Award of the Russian Federation President for the therapeutic substance Panagen. The technology of incubation of the non-manipulated cells of bone marrow and HSCs with the approved therapeutic substance Panagen opens a unique opportunity for molecular-biological stabilization of the unstable genome, permitting the opportunity to compensate the clinical condition in the cases of various hereditary, oncological and autoimmune diseases by replacement infusion of molecular-biologically restored HSC and HPCs. Integration of cell and postgenomic technologies without genome editing permits restoration of the hematopoiesis in mammals even after three- or even five-fold increase of the dose of the lethal ionizing radiation of their HSCs. The approach is supposed to be able to arrest proliferation in a cancer stem cell (CSC) in different types of cancer and prevents the fatal aplasia of the bone marrow in chemo- and radiotherapy.
Over 20 years’ experience of chemo-, radio- and palliative therapy in severe cases of cancer, led to the development of the oncoimmunological biomedical platform. Its goal is to increase the survival rates, lifespan of the patients and to improve the efficacy of rehabilitation. We offer solutions to these problems using the technologies of regenerative medicine (see details). All technologies are patented and tested in experimental animals and humans with the help of the leading experts of the Federal Research Centers of the Ministry of Healthcare and Russian Academy of Science. The co-authors of our patents are Sukhikh GT, the member of RAS, Yaryghin VN, the member of RAS, Chekhonin VP, the member of RAS, Davydov MI, the member of RAS and many others.
Our broad experience of using non-manipulated and low manipulated cell products of HSCs proved safe as there have not been a single case of cell therapy induced cancer, disability or death. The effectiveness and safety of the cell product is based on our know-how when the stem cells are expanded and restored without culturing and development of a cell line. We discovered a nature-like mechanism of restoration and compensation of the unstable genome of the cells in certain hereditary neural diseases, autoimmune and neurodegenerative disease; and this mechanism is almost a complete alternative to genome editing. It opens a unique opportunity to develop innovative individually tailored methods of compensation of some of the conditions induced by the incurable disorders.
